Home › Targets › CD20
CD20 (6 companies · 24 programs)
Companies with an active program directed at CD20.
- AlloNK — Rheumatoid Arthritis Phase 1
- AlloNK — Sjögren's Disease Phase 2
- AlloNK — Systemic Sclerosis Phase 2
- AlloNK — Idiopathic Inflammatory Myopathies Phase 2
- AlloNK — Systemic Lupus Erythematosus Phase 1
- AlloNK — Lupus Nephritis Phase 1
- AlloNK — Pemphigus Vulgaris Phase 1
- AlloNK — ANCA-Associated Vasculitis Phase 1
- prula-cel — Lupus Nephritis Phase 1
- prula-cel — Systemic Lupus Erythematosus Phase 1
- prula-cel — Systemic Sclerosis Phase 1
- prula-cel — Idiopathic Inflammatory Myopathies Phase 1
- prula-cel — Stiff Person Syndrome Phase 1
- prula-cel — Anti-Neutrophil Cytoplasmic Autoantibody Associated Vasculitis Phase 1
- prula-cel — Rheumatoid Arthritis Phase 1
- BRIUMVI — Relapsing Forms of Multiple Sclerosis Approved
- BRIUMVI — Myasthenia Gravis Phase 1
- BRIUMVI — Relapsing Forms of Multiple Sclerosis Phase 3
- BRIUMVI — Schizophrenia Phase 2
- BRIUMVI — Myasthenia Gravis Phase 2
- plamotamab — Rheumatoid Arthritis Phase 1
- JNJ-1493 — B-Cell Lymphoma Phase 1
- LUCAR-G39D — Non-Hodgkin Lymphoma Phase 1
